Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA- 134a in patients with asthma

Annals of Allergy, Asthma and Immunology

Volumn 83, Issue 4, 1999, Pages 327-333

  Jacobson, Kraig ^a   Chervinsky, Paul ^b   Noonan, Michael ^c   Kane, Robert E ^d,e   Banerji, Donald ^d   Uryniak, Thomas ^d  

^a Allergy and Asthma Research Group   (United States)

^b New England Clinical Studies   (United States)

^c Allergy Associates Research Center   (United States)

^d Rhône Polenc Rorer   (United States)

^e SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NORFLURANE; PROPELLANT; SALBUTAMOL; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPEPSIA; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFECTION; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS;

EID: 0032742217     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62673-7     Document Type: Article

References (15)

1. Williams MH Jr, Kane C, Shim CS. Treatment of asthma with triamcinolone acetonide delivered by aerosol. Am Rev Respir Dis 1974;109: 538-543.
2. Bernstein IL, Chervinsky P, Falliers CJ. Efficacy and safety of triamcinolone acetonide aerosol in chronic asthma. Results of a multicenter, short-term controlled and long-term open study. Chest 1982;81:20-26.
3. Falliers CJ, Petraco AJ. Control of asthma with triamcinolone acetonide aerosol inhalations at 12 hour intervals. J Asthma 1982;19:241-247.
4. Bernstein DI, Cohen R, Ginchansky E, et al. A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 μg per day) for the treatment of patients with mild-to-moderate asthma. J Allergy Clin Immunol 1998;101:433-438.
5. Newman SP. Metered dose pressurized aerosols and the ozone layer. Eur Respir J 1990;3:495-497.
6. Noakes TJ. CFCs, their replacements and the ozone layer. J Aerosol Med 1995;8(suppl 1):S3-7.
7. Smith IJ. The challenge of reformulation. J Aerosol Med 1995;8(suppl 1): S19-27.
8. Fisher DA, Hales CH. Model calculations of the relative effects of CFCs and their replacements on global warming. Nature 1990;344:513-516.
9. CPMP on Possible Alternatives of CFCs. Scrip 1994;1943:26.
10. United States Pharmacopeial Convention: Dosage unit sampling for metered-dose inhalers. Pharmacopeial Forum 1998;24:6940-6942.
11. Welch M, Levy S, Smith J, et al. Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. Chest 1997;112: 597-606.
12. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994;94:676-683.
13. Busse W. Dose related efficacy of Pulmicort® (budesonide) Turbohaler® in moderate to severe asthma. J Allergy Clin Immunol 1994;94:186.
14. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:1-52.
15. D'Souza S. Montreal protocol and essential use exemptions. J Aerosol Med 1995;8(suppl 1):S13-S17.